Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q2 EPS results and issued FY23 guidance. Additionally, RBC Capital raised its price target from $522 to $524 on the stock.
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories reported better-than-expected Q2 EPS results and issued FY23 guidance, leading to a rise in its share price. RBC Capital also raised its price target for the company from $522 to $524.
August 04, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Rad Laboratories' better-than-expected Q2 EPS results and FY23 guidance, along with RBC Capital's raised price target, have led to a rise in its share price.
Bio-Rad Laboratories' strong Q2 EPS results and positive FY23 guidance indicate a healthy financial performance, which is a positive signal to investors. Additionally, RBC Capital's raised price target suggests a positive outlook for the company's stock, further boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100